NCT03158324View on ClinicalTrials.gov

Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

PHASE2UnknownINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

May 22, 2020

Study Completion Date

November 30, 2020

Conditions
NPCRefractory Tumor
Interventions
DRUG

OPB-111077

Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity

Trial Locations (1)

119228

RECRUITING

National University Hospital, Singapore, Singapore

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

National University Hospital, Singapore

OTHER